2004
Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
1993
Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals
Silberstein C, O’dowd M, Schoenbaum E, Friedland G, Chartock P, Feiner C, Mckegney F. Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals. Journal Of The Academy Of Consultation-Liaison Psychiatry 1993, 34: 502-505. PMID: 8284340, DOI: 10.1016/s0033-3182(93)71824-1.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) disease progressionHIV-positive asymptomatic patientsCentral nervous system impairmentHIV-seropositive individualsNervous system impairmentBaseline neuropsychological functionProgressive HIVAsymptomatic HIVAsymptomatic patientsPoorer baseline scoresImmunologic dysfunctionSystemic symptomsDisease progressionNeuropsychological dysfunctionBaseline scoresNeuropsychological functionHIVPatientsSystem impairmentStudy periodNeuropsychological testsNeuropsychological markersDysfunctionProgressionHigher scores
1992
High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy
Selwyn P, Sckell B, Alcabes P, Friedland G, Klein R, Schoenbaum E. High Risk of Active Tuberculosis in HIV-Infected Drug Users With Cutaneous Anergy. JAMA 1992, 268: 504-509. PMID: 1619742, DOI: 10.1001/jama.1992.03490040080029.Peer-Reviewed Original ResearchConceptsHIV serological statusAnergic subjectsActive tuberculosisTuberculin reactorsCutaneous anergyDrug injectorsIsoniazid chemoprophylaxisIsoniazid prophylaxisHIV infectionTuberculosis incidenceTuberculin testingSerological statusHigh riskDelayed-type hypersensitivity skin testingDelayed-type hypersensitivity testingPositive tuberculin test resultsStudy periodAdvanced HIV diseaseHIV disease statusMonths of prophylaxisT lymphocyte levelsHypersensitivity skin testingProspective observational studyTuberculosis incidence rateMycobacterium tuberculosis infection
1988
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS
Selwyn P, Feingold A, Hartel D, Schoenbaum E, Alderman M, Klein R, Friedland G. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988, 2: 267-272. PMID: 3140832, DOI: 10.1097/00002030-198808000-00005.Peer-Reviewed Original ResearchConceptsIntravenous drug usersIntravenous drug useBacterial pneumoniaHIV infectionDrug usersDrug useActive intravenous drug useCommunity-acquired bacterial pneumoniaCumulative yearly incidenceMethadone maintenance programSeronegative subjectsSeropositive patientsSeropositive subjectsStudy entryOpportunistic infectionsYearly incidencePneumoniaHemophilus influenzaeStreptococcus pneumoniaeSeropositivesHIVAIDSInfectionStudy periodIncidence